#United States #Ractigen Therapeutics #Nantong #RAG-1C #saRNA therapy

Ractigen Therapeutics Achieves FDA IND Clearance for RAG-1C

In a significant advancement within the biopharmaceutical sector, Ractigen Therapeutics has recently secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its innovative saRNA (small activating RNA) candidate known as RAG-1C. This therapy is aimed at preventing and treating Proliferative Vitreoretinopathy (PVR), a serious ocular condition that can lead to severe vision loss. The achievement positions Ractigen Therapeutics as a frontrunner in the development of saRNA therapies, which are designed to activate specific genes to elicit therapeutic effects.

Context of the Approval

The approval from the FDA follows the earlier clearance from China’s National Medical Products Administration (NMPA), demonstrating a strategic move to position RAG-1C as a globally recognized therapy for PVR. Proliferative Vitreoretinopathy is particularly known for its complicating role in retinal detachment cases, occurring after events such as rhegmatogenous retinal detachment or ocular trauma. Currently, surgical options dominate the treatment landscape, leaving a gap for effective pharmacological therapies, as no drugs have gained FDA approval for PVR treatment.

Understanding PVR

PVR accounts for up to 10% of all retinal detachment surgeries, with rates soaring to 40% in severe trauma cases. The condition is characterized by abnormal proliferation and migration of retinal pigment epithelium (RPE) cells and fibroblasts, ultimately leading to complications such as tractional retinal detachment and irreversible vision loss. The high failure rates associated with existing surgical procedures underscore the urgent need for effective alternative treatments.

The Role of RAG-1C

What sets RAG-1C apart is its delivery mechanism and gene-targeting capability derived from Ractigen’s proprietary LiCO™ (Lipid-Conjugated Oligonucleotide) platform. This ground-breaking technology optimally delivers saRNA to its target without the systemic exposure typical of other treatment modalities. By upregulating the expression of the p21 gene, RAG-1C promotes cell cycle arrest in retinal cells. This mechanism effectively inhibits unwanted cell proliferation and myofibroblast transformation, crucial in addressing the fibrotic processes associated with PVR.

Administered through an intravitreal injection, RAG-1C represents a paradigm shift due to its potential for long-lasting anti-fibrotic protection with a single treatment—a concept often referred to as “One-and-Done.”

The Path Forward

Moving forward, Ractigen plans to initiate a Phase I clinical trial to further assess the safety, tolerability, and efficacy of RAG-1C. The trial will involve patients undergoing surgery for retinal detachment who are at high risk for developing PVR, establishing a clear pathway for potential future applications of the drug. Dr. Long-Cheng Li, the company’s founder and CEO, emphasized that this FDA clearance not only validates the safety of RAG-1C but underscores Ractigen’s leadership in RNA activation technology.

Ractigen's Commitment

Ractigen Therapeutics continues to lead the charge in developing the next generation of RNA-based therapies. By focusing on unmet medical needs in various fields including oncology and neurological disorders, the company is dedicated to harnessing the power of RNA to enhance clinical outcomes and improve quality of life for patients worldwide. The validation of RAG-1C represents a crucial step in transforming treatment paradigms for previously tough-to-treat conditions such as PVR.

For further information about Ractigen Therapeutics and its innovative solutions, visit www.ractigen.com.